CDT Equity Inc. Initiates Reverse Stock Split and Expands Solid‑Form Licensing Strategy

CDT Equity Inc. (NASDAQ: CDT), a disease‑agnostic life science company headquartered in San Del­a, announced that it will execute a reverse stock split. The move, disclosed on January 2, 2026 at 13:32 UTC by Globe News Wire, aims to consolidate shares and support the company’s market‑cap structure. The reverse split is expected to increase the per‑share price while maintaining the overall market value.

On the same day, the company reported a strategic partnership with NJS Foresight. According to an investment‑focused release from Investing.com at 13:54 UTC, CDT is engaging NJS Foresight to out‑license solid‑form patent assets. The arrangement will leverage NJS Foresight’s expertise in bio‑advisory services to identify and develop commercial opportunities for CDT’s solid‑form portfolio. A complementary announcement appeared on TaiwanNews.com at 13:42 UTC, reiterating the collaboration and emphasizing the company’s intent to broaden its out‑licensing reach within the solid‑form domain.

Company Context

  • Sector: Health Care
  • Primary Exchange: Nasdaq
  • Currency: USD
  • Recent Share Performance:
  • Close price on 2025‑12‑30: $1.28
  • 52‑week high (2025‑01‑09): $2,196
  • 52‑week low (2025‑12‑30): $1.26
  • Market Capitalization: $2,090,000
  • Price‑to‑Earnings Ratio: –0.01

CDT’s business model focuses on accelerating the development of clinical assets that have been deprioritized by other pharmaceutical companies. The firm’s mission is to bring new treatments to patients more efficiently, targeting customers primarily within the United States.

Strategic Implications

  1. Reverse Stock Split
  • Consolidates existing shares, potentially improving liquidity and making the stock more attractive to institutional investors.
  • Aligns the share price with market expectations for a company of its size.
  1. NJS Foresight Partnership
  • Expands CDT’s licensing pipeline, specifically in solid‑form technology, a critical area for drug delivery and formulation.
  • Positions CDT to monetize intellectual property that may otherwise remain underutilized.

Outlook

The reverse split is expected to take effect shortly after approval by the Nasdaq. The out‑licensing initiative with NJS Foresight is anticipated to generate additional revenue streams and strengthen CDT’s market position in the life‑science sector. Investors should monitor the implementation timeline and any subsequent licensing agreements that arise from this partnership.